Advertisement

Topics

Millennium: The Takeda Oncology Company Company Profile

03:56 EDT 25th March 2019 | BioPortfolio

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company’s research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.


News Articles [1175 Associated News Articles listed on BioPortfolio]

LegoChem and Takeda Partner for the Development of Antibody-Drug Conjugates in Immuno-Oncology

DAEJEON, South Korea–(BUSINESS WIRE)–LegoChem Biosciences, Inc. (“LCB”) (KOSDAQ:141080) announced today that it has entered a research collaboration and license agreement with Tak...

Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody®

CAMBRIDGE, England–(BUSINESS WIRE)–Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Comp...

Takeda strikes three new immuno-oncology deals

Takeda is upping its commitment to cancer after its Shire takeover with the announcement of three new research collaborations in immuno-oncology. In the first deal, Takeda will collaborate with Memor...

Millennium:Looking for First in Class and Best in Class Opportunities in Oncology and Hematology

In this episode of PharmaTelevision News Review, filmed at #BIO2012 Convention in Boston, Fintan Walton talks to Dan Curran, Vice President, Corporate Development at Millennium

‘An incredible opportunity’: Takeda signs immuno-oncology collaborations

Takeda entered multiple research collaborations for immuno-oncology and CAR-T therapies, an area of strategic focus for the company.

Takeda Licenses Oncology Target from Crescendo Biologics

Acting on an option out of 2016 collaboration deal, Japan’s Takeda Pharmaceutical licensed Humabodies directed to one of its oncology targets from Cambridge, UK’s Crescendo Biologics.

Takeda Receives Positive European Agency Opinion Recommending Alunbrig

NewsAlunbrig is a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

Takeda forms new alliances to boosts immuno-oncology portfolio

Takeda Pharmaceutical has formed new research alliances to bolster the discovery of next-generation immunotherapies, including cell therapy techniques, for the...Read More... The post Takeda forms new...

Drugs and Medications [371 Associated Drugs and Medications listed on BioPortfolio]

Iclusig [millennium pharmaceuticals, inc.]

These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG(ponatinib) tablets, for oral use Initial U.S. Ap...

Nesina [takeda pharmaceuticals america, inc.]

These highlights do not include all the information needed to use NESINA safely and effectively. See full prescribing information for NESINA. NESINA (alogliptin) tablets, for oral use Initial U.S. App...

Oxygen [island equipment company]

Oxygen

Oxygen [support medical company]

Oxygen

Oxygen [lowry drug company inc. ]

Oxygen

PubMed Articles [1345 Associated PubMed Articles listed on BioPortfolio]

IMRT/VMAT dose distributions generated for and collimators and accelerators.

The aim of this study is to answer the question whether the calculated dose distributions for HD and Millennium collimators (Varian Medical Systems) are equivalent for large treatment volumes.

Epidemiologic challenges in norovirus vaccine development.

Norovirus is the leading cause of acute gastroenteritis (AGE) worldwide. In the United States norovirus is estimated to cause 19-21 million illnesses, 1.7-1.9 million outpatient visits, 56,000-71,00...

Assessing the performance of the least developed countries in terms of the Millennium Development Goals.

This article presents a proposal for assessing the progress of least developed countries towards the achievement of the Millennium Development Goals over the period 2000-2015. Composite indices are bu...

A Man (or a Woman) is Known by the Company He/She Keeps.

Communication training in oncology needs a theoretical framework.

Clinical Trials [709 Associated Clinical Trials listed on BioPortfolio]

A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules

The purpose of this study is to assess the BA of 30 or 60 milligram (mg) dexlansoprazole capsule manufactured at TOB (Takeda GmbH Plant Oranienburg) to the corresponding 30 or 60 mg dexlan...

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

The purpose of this study is to assess the bioavailability of dexlansoprazole from a 30 milligram (mg) or 60 mg delayed-release capsule manufactured at Takeda GmbH Plant Oranienburg, Germa...

The Millennium Villages Project: Assessing the Impact on Child Survival and the Millennium Development Goals in Sub-Saharan Africa

The Millennium Villages Project involves the coordinated and simultaneous delivery of a package of proven interventions in health, agriculture, infrastructure and education. The project wo...

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Dexlansoprazole from Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant...

Companies [2306 Associated Companies listed on BioPortfolio]

Millennium: The Takeda Oncology Company

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets a first-in-class proteasome inhibitor, and has a robust clinical de...

Millennium Dental Technologies, Inc.

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a first-in-class proteasome inhibitor, and has a robust cl...

Takeda Oncology

Takeda Oncology, headquartered in Cambridge, MA, delivers novel medicines to patients with cancer worldwide through its commitment to science, breakthrough innovation and passion ...

Millennium Pharmaceuticals, Inc.

Millennium Pharmaceuticals, The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical developme...

Millennium: The Takeda Oncology Company and Seattle Genetics, Inc.

More Information about "Millennium: The Takeda Oncology Company" on BioPortfolio

We have published hundreds of Millennium: The Takeda Oncology Company news stories on BioPortfolio along with dozens of Millennium: The Takeda Oncology Company Clinical Trials and PubMed Articles about Millennium: The Takeda Oncology Company for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Millennium: The Takeda Oncology Company Companies in our database. You can also find out about relevant Millennium: The Takeda Oncology Company Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...


Corporate Database Quicklinks



Searches Linking to this Company Record